SynAct Pharma AB (publ) today announced that it has terminated its agreement with Sedemera Fondkommission to act as the company’s liquidity provider.
SynAct Pharma’s last trading day with a liquidity provider is November 13, 2020.
For further information about SynAct Pharma AB, please contact:
Jeppe Øvlesen Thomas Jonassen
CEO, SynAct Pharma AB CSO, SynAct Pharma AB
Phone: +45 28 44 75 67 Phone: +45 40 15 66 69
Mail: [email protected] Mail: tj@synactpharma.com